An Epidemiological Study Aimed to Record Standard Daily Practice in Managing Patients With Hypercholesterolemia
Launched by ASTRAZENECA · Sep 20, 2010
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with hypercholesterolemia currently receiving a lipid lowering agent
- Exclusion Criteria:
- • Pregnancy and lactation.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Belgrade, , Serbia
Cacak, , Serbia
Kragujevac, , Serbia
Sremska Kamenica, , Serbia
Nis, , Serbia
Niska Banja, , Serbia
Pancevo, , Serbia
Pozarevac, , Serbia
Sombor, , Serbia
Uzice, , Serbia
Patients applied
Trial Officials
Prof.Dr Miodrag Ostojic
Principal Investigator
Division of Cardiology-Clinical Centre of Serbia-Belgrade
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials